1,014 reports of this reaction
6.0% of all BLINATUMOMAB reports
#3 most reported adverse reaction
CYTOKINE RELEASE SYNDROME is the #3 most commonly reported adverse reaction for BLINATUMOMAB, manufactured by Amgen, Inc. There are 1,014 FDA adverse event reports linking BLINATUMOMAB to CYTOKINE RELEASE SYNDROME. This represents approximately 6.0% of all 16,815 adverse event reports for this drug.
Patients taking BLINATUMOMAB who experience cytokine release syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CYTOKINE RELEASE SYNDROME is moderately reported among BLINATUMOMAB users, representing a notable but not dominant share of adverse events.
In addition to cytokine release syndrome, the following adverse reactions have been reported for BLINATUMOMAB:
The following drugs have also been linked to cytokine release syndrome in FDA adverse event reports:
CYTOKINE RELEASE SYNDROME has been reported as an adverse event in 1,014 FDA reports for BLINATUMOMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
CYTOKINE RELEASE SYNDROME accounts for approximately 6.0% of all adverse event reports for BLINATUMOMAB, making it one of the most commonly reported side effect.
If you experience cytokine release syndrome while taking BLINATUMOMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.